Mapping individual multiple myeloma biology to understand relapse and treatment resistance

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, observational effort enrolling adults with monoclonal gammopathy or active multiple myeloma, conducted retrospectively and prospectively. The study links detailed clinical data with advanced molecular analyses, including whole-genome sequencing, RNA sequencing, and circulating tumor markers. Samples and data will be securely stored and analyzed to identify biological and clinical factors tied to disease progression and therapy response. The aim is to build a comprehensive map of disease heterogeneity to inform more personalized treatment approaches in the future.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18+
* Signed CI for study partecipation and personal data processing.
* Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM)

Exclusion Criteria:

* None

Where it's running

• IRCCS AOU Policlinico Sant'Orsola
  Bologna, Bo, Italy Recruiting

Study contacts

• Study coordinator: Carolina Terragna, MD
• Email: carolina.terragna@unibo.it
• Phone: 0512143831

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Immune Fitness in Older Adults with Relapsed or Refractory Multiple Myeloma

  This study checks whether immune health before treatment can predict how well older adults with relapsed or refractory multiple myeloma respond to CAR-T or bispecific antibody therapies.

  Recruiting Jules Bordet Institute · Anderlecht, Brussels Capital and 2 other locations · NCT07674498

• Infectious complications in blood cancer patients treated with bispecific antibodies

  This study tests how often infections occur in adults with blood cancers who are being treated with bispecific antibodies.

  Recruiting at 2 sites Infanta Leonor University Hospital · Madrid, Madrid and 1 other locations · NCT07609576

• Multi-omics testing for blood and bone marrow cancers

  This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, PR · NCT07445438

• Anonymizing and combining past clinical, genetic, and imaging data from people with multiple myeloma to build AI prediction models.

  This project will try to use already-collected clinical, genetic, and imaging data from adults with multiple myeloma to build AI models that predict disease progression and treatment response, with no new visits or tests required.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bo · NCT07283224

• e-Motion: Promoting Emotion Regulation for People Living with Chronic Cancer

  This pilot tests two emotion-regulation programs—a guided self-help program and a combined group plus guided self-help program—for people recently diagnosed with metastatic or other chronic cancers.

  Recruiting Université Libre de Bruxelles · Brussels, Anderlecht and 1 other locations · NCT07236021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.